Secondary Hypertension in Children and Adolescents: Novel Insights.
Adolescent
Age Factors
Antihypertensive Agents
/ therapeutic use
Blood Pressure
/ drug effects
Blood Pressure Monitoring, Ambulatory
Child
Humans
Hypertension
/ diagnosis
Premature Birth
/ epidemiology
Renal Insufficiency, Chronic
/ epidemiology
Risk Factors
Risk Reduction Behavior
Treatment Outcome
Children
ambulatory blood pressure
chronic kidney disease
diagnosis
hypertension
prematurity.
Journal
Current hypertension reviews
ISSN: 1875-6506
Titre abrégé: Curr Hypertens Rev
Pays: United Arab Emirates
ID NLM: 101239891
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
03
2019
revised:
31
03
2019
accepted:
01
04
2019
pubmed:
1
5
2019
medline:
23
12
2020
entrez:
1
5
2019
Statut:
ppublish
Résumé
Hypertension is a significant risk factor for cardiovascular morbidity and mortality, not only in adults, but in youths also, as it is associated with long-term negative health effects. The predominant type of hypertension in children is the secondary hypertension, with the chronic kidney disease being the most common cause, however, nowadays, there is a rising incidence of primary hypertension due to the rising incidence of obesity in children. Although office blood pressure has guided patient management for many years, ambulatory blood pressure monitoring provides useful information, facilitates the diagnosis and management of hypertension in children and adolescents, by monitoring treatment and evaluation for secondary causes or specific phenotypes of hypertension. In the field of secondary hypertension, there are numerous studies, which have reported a strong association between different determinants of 24-hour blood pressure profile and the underlying cause. In addition, in children with secondary hypertension, ambulatory blood pressure monitoring parameters offer the unique advantage to identify pediatric low- and high-risk children for target organ damage. Novel insights in the pathogenesis of hypertension, including the role of perinatal factors or new cardiovascular biomarkers, such as fibroblast growth factor 23, need to be further evaluated in the near future.
Identifiants
pubmed: 31038068
pii: CHYR-EPUB-98112
doi: 10.2174/1573402115666190416152820
doi:
Substances chimiques
Antihypertensive Agents
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
37-44Informations de copyright
Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.